Abstract: Multi-dose formulations for bortezomib are presented in which bortezomib has significantly improved stability. Especially preferred formulations include those in which bortezomib is in a liquid form suitable for injection, wherein the solvent system predominantly comprises propylene glycol. In other preferred aspects, bortezomib is present as a Lewis donor-acceptor complex with a hetero-bifunctional Lewis base.

Abstract: Multi-dose formulations for bortezomib are presented in which bortezomib has significantly improved stability. Especially preferred formulations include those in which bortezomib is in a liquid form suitable for injection, wherein the solvent system predominantly comprises propylene glycol. In other preferred aspects, bortezomib is present as a Lewis donor-acceptor complex with a hetero-bifunctional Lewis base.

Abstract: Multi-dose formulations for bortezomib are presented in which bortezomib has significantly improved stability. Especially preferred formulations include those in which bortezomib is in a liquid form suitable for injection, wherein the solvent system predominantly comprises propylene glycol. In other preferred aspects, bortezomib is present as a Lewis donor-acceptor complex with a hetero-bifunctional Lewis base.

Abstract: Multi-dose formulations for bortezomib are presented in which bortezomib has significantly improved stability. Especially preferred formulations include those in which bortezomib is in a liquid form suitable for injection, wherein the solvent system predominantly comprises propylene glycol. In other preferred aspects, bortezomib is present as a Lewis donor-acceptor complex with a hetero-bifunctional Lewis base.

Abstract: Provided is a method of treating a patient having a tissue that is subject to an ischemic event. The method is conducted by parenterally administering a formulation containing a halogenated volatile anesthetic in an amount effective to improve the tissue's resistance to or tolerance of the ischemic event. In preferred embodiment of the invention, the amount of the formulation administered to the patient is sub-anesthetic. The formulation can be administered prior to, concurrently with, or after the ischemic event. The method can be used, for example, for treatment of patients having myocardial or neuronal tissue that is subject to an ischemic event.

Abstract: Stable, pharmaceutical compositions including a synthetic motilin-like peptide in a buffered solution are disclosed. The composition provides for a peptide that remains stable and substantially retains its initial potency during extended storage and after steam sterilization.

Abstract: Stable, pharmaceutical compositions including a synthetic motilin-like peptide in a buffered aqueous solution or in an unbuffered aqueous solution are disclosed. The composition provides for a peptide that remains stable and substantially retains its initial potency during extended storage and after steam sterilization.

Abstract: The invention is directed to a process for preparing a pharmaceutical formulation containing two or more active pharmaceutical ingredients comprising: (a) contacting two or more active pharmaceutical ingredients with a supercritical fluid to form a supercritical fluid solution; and (b) separating the active ingredients from the supercritical solution to yield a powder precipitate. Preferably, the pharmaceutical formulation prepared according to the invention contains a combination of two anti-infective agents or two anticancer agents. The invention is further directed to a process for preparing a pharmaceutical formulation containing two or more active pharmaceutical ingredients comprising: (a) combining two or more active ingredients with a cosolvent to form a solution; (b) contacting the solution with a supercritical fluid; and (c) recovering the precipitate in a powder form.

Abstract: The invention is directed to a process for preparing a pharmaceutical formulation containing two or more active pharmaceutical ingredients comprising: (a) combining two or more active pharmaceutical ingredients with a supercritical fluid to form a supercritical fluid solution; and (b) separating the active ingredients from the supercritical solution to yield a dry powder precipitate. Preferably, the pharmaceutical formulation prepared according to the invention contains a combination of two anti-infective agents. The invention is further directed to a process for preparing a pharmaceutical formulation containing two or more active pharmaceutical ingredients comprising: (a) combining two or more active ingredients with a cosolvent to form a solution; (b) mixing the solution with a supercritical fluid; and (c) recovering the precipitate in a dry powder form.

Abstract: Provided is a method of treating a patient having a tissue that is subject to an ischemic event. The method is conducted by parenterally administering a formulation containing a halogenated volatile anesthetic in an amount effective to improve the tissue's resistance to or tolerance of the ischemic event. In preferred embodiment of the invention, the amount of the formulation administered to the patient is sub-anesthetic. The formulation can be administered prior to, concurrently with, or after the ischemic event. The method can be used, for example, for treatment of patients having myocardial or neuronal tissue that is subject to an ischemic event.